The CARTO 3 System offers three unique features: Advanced Catheter Location (ACL) technology, the rapid anatomical mapping (FAM), and a function called with the workflow easy connection of choice. These three functions work together to improve the ability of a physician to treat a range of simple and complex cardiac arrhythmias.The CARTO 3 System is the latest in a series of innovations from Biosense Webster. In recent months, the company launched the NAVISTAR RMT ThermoCool catheter in the U.S. and Europe and the EZ STEER Bi-directional catheter ThermoCool United States
FAM is a technology that creates fast and accurate high-resolution CT, as the maps as soon as an EP can move the catheter through the heart chamber. FAM technology also allows detailed visual improvement in a specific area of interest in the heart.
Biosense Webster, Inc., a global leader in the diagnosis and treatment of heart disease, announced today that the Food and Drug Administration (FDA) has granted permission marketing system CARTO 3, the most advanced imaging technology in three dimensions for use by electrophysiologists in the treatment of cardiac arrhythmias, commonly known as irregular heartbeat.
The CARTO 3 System is an interesting technology that represents an important step forward for electrophysiologists. I was able to create a map quickly and accurately has been excellent, said Vivek Y. Reddy, MD, Director, Cardiac Arrhythmia Service, The Zeng and Michael A. Wiener Cardiovascular Institute, The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health. Dr. Reddy is also Professor of Medicine Mount Sinai School of Medicine in New York. Also, I was happy with how the system merged with our scanners. Overall, the evaluation was a great experience for the entire team workshop, who appreciated the new system in place quickly.
Connection option is enabled for the new hardware configuration of the CARTO brand with a central connection point for all catheters and equipment, while preserving the signal quality of intracardiac electrograms. Catheter connections have been redesigned to plug and play functionality and automatic recognition of the catheter. All these improvements have been developed to streamline and simplify the workflow in the EP lab.
Earlier this year, the FDA approved the NAVISTAR ThermoCool catheter, EZ Steer including bi-directional catheter platform, as safe and effective for the treatment of drug refractory recurrent symptomatic paroxysmal when used with the Carto system. NAVISTAR ThermoCool catheter ablation catheters are the first and only FDA-approved for the treatment of atrial fibrillation.
The CARTO 3 System is the world’s most sophisticated 3D mapping platform currently on the market and builds on our long-standing commitment to electrophysiologists and their patients, said Shlomi Nachman, Worldwide President, Biosense Webster, Inc.
The time of the procedure is regularly quoted by EP as the main obstacle to increased use of ablation therapy for the treatment of cardiac arrhythmias, said Nachman. All the improvements offered by the CARTO system were developed for three streamline and simplify the workflow in the laboratory of the European Parliament.